A Phase 4 interventional study of Single Antiplatelet Therapy or No Therapy (Control) and Non-Antithrombotic Therapy in Nonvalvular Atrial Fibrillation, Aspirin and Non-Antithrombotic Therapy, sponsored by OCEAN-SHD Study Group. Recruiting at 21 sites in Japan. Per ClinicalTrials.gov, last updated 2025-08-15.
Sponsored by OCEAN-SHD Study Group · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Atrial Fibrillation with a site in Japan — 7 open to participants now, 13 under way, 3 of them phase 3. Atrial Fibrillation · Japan.
Among the 84 studies in Atrial Fibrillation with a site in Japan, this one is the 28th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 4, reaches primary completion later than 11 of the 12 other live ones, and was the 81st registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →7 of the 84 studies in Atrial Fibrillation with a site in Japan are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
Regeneron Pharmaceuticals · Sites in Japan, United States, Canada
Ages 18+
Kitasato University · Sites in Japan
Ages 18–85
Anthos Therapeutics, Inc. · Sites in Japan, United States, Argentina and 32 more countries
Ages 65+
Diagram B.V. · Sites in Japan, France, Netherlands
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 15 · Phase 4 10
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 500 across the 55 interventional studies, 5,000 across the 29 observational. Of the 61 that completed or were terminated, 36 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 84 have an industry lead sponsor. The 10 most frequent:
OCEAN-SHD Study Group is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
OCEAN-SHD Study Group has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies in Atrial Fibrillation with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07870837iRhythm Technologies, Inc.Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan | 2027-03-31 |
| NCT04428944McGill University Health Centre/Research Institute of the McGill University Health CentreSTrategies for Catheter Ablation of peRsistent Atrial Fibrlllation | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Atrial Fibrillation with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet Therapy (SAPT) with aspirin during the period from randomization to the end of observational period (4 years at the maximum) in non-valvular atrial fibrillation subjects with high bleeding risk.
The primary endpoint is a composite endpoint consisting of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding from randomization to the end of study observation (up to a maximum follow-up of 4 years).
\<Study treatment duration> In both arms, OAC monotherapy will be initiated in the first 24 hours of enrollment and continued for 45 days (allowed window period: plus 2 weeks)..
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who meet one or more of the following criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Single Antiplatelet Therapy or No Therapy (Control)
Other: Non-Antithrombotic Therapy
Monotherapy with oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) and vitamin K antagonist oral anticoagulants (VKA) for 45 days after left atrial appendage closure (LAAC), followed by aspirin-directed antiplatelet monotherapy (Single Antiplatelet Therapy: SAPT) through the end of the observational period.
Monotherapy with OAC for 45 days after LAAC, followed by no antithrombotic therapy (Non-Antithrombotic Therapy: NAPT) from enrollment through the end of the observational period.
A composite endpoint consisting of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding
The definition of major bleeding or clinically significant nonfatal bleeding for the primary endpoint is BARC type 2, 3, or 5 bleeding among BARC type 1, 2, 3, 4, and 5. Surviving cases with no events shall be censored as of the date of discontinuation of study treatment or the date of last confirmation of survival. Planned enrollment term is two years, and all subjects will be obsserved until 4 years after first enrollment.
Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.
Non-procedure-related BARC bleeding events of Type 1 or greater
Non-procedure-related was defined as occurring after 7 days after the LAAC procedure. It will be assessed throughout the entire study period, as well as from the day following Visit 1 (occurring 46 to 60 days post-randomization) until the end of the study.
Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.
ISTH major bleeding not related to the procedure and clinically relevant non-fatal bleeding
Not related to the procedure refers to events occurring 7 days after the LAAC procedure. It will be assessed throughout the entire study period, as well as from the day following Visit 1 (occurring 46 to 60 days post-randomization) until the end of the study.
Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.
Incidence of device-related thrombus (DRT) detected by CT and/or transesophageal echocardiography (TEE)
Time frame: at Visit 1 (46~60days after randomization), 1 year, and 2 years after randomization
Combined endpoint consisting of the occurrence of ischemic stroke and systemic embolism
It will be assessed throughout the entire study period, as well as from the day following Visit 1 (occurring 46 to 60 days post-randomization) until the end of the study.
Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.
Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 48 months is close to that.
Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
OCEAN-SHD Study Group